[go: up one dir, main page]

AR101476A1 - Métodos para tratar cánceres, enfermedades inmunes y autoinmunes, y enfermedades inflamatorias en base a la tasa de ocupación de la tirosin quinasa de bruton (btk) y a la tasa de resíntesis de la tirosin quinasa de bruton (btk) - Google Patents

Métodos para tratar cánceres, enfermedades inmunes y autoinmunes, y enfermedades inflamatorias en base a la tasa de ocupación de la tirosin quinasa de bruton (btk) y a la tasa de resíntesis de la tirosin quinasa de bruton (btk)

Info

Publication number
AR101476A1
AR101476A1 ARP150102547A ARP150102547A AR101476A1 AR 101476 A1 AR101476 A1 AR 101476A1 AR P150102547 A ARP150102547 A AR P150102547A AR P150102547 A ARP150102547 A AR P150102547A AR 101476 A1 AR101476 A1 AR 101476A1
Authority
AR
Argentina
Prior art keywords
btk
quinask
immune
bruton
typosin
Prior art date
Application number
ARP150102547A
Other languages
English (en)
Original Assignee
Acerta Pharma Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Acerta Pharma Bv filed Critical Acerta Pharma Bv
Publication of AR101476A1 publication Critical patent/AR101476A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dermatology (AREA)
  • Transplantation (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)

Abstract

Métodos terapéuticos, composiciones y usos de un inhibidor de Tirosina Quinasa de Bruton (BTK) para tratamiento del cáncer, inflamación, trastornos inmunes, y enfermedades autoinmunes, y para profilaxis de trasplante, en base a ocupación de la BTK y/o tasas de resíntesis de la BTK para células B en diversas enfermedades, compartimentos de tejidos, incluyendo médula ósea y nódulos linfáticos. Regímenes de dosificación para un inhibidor de la BTK para tratamiento del cáncer, inflamación, trastornos inmunes, y enfermedades autoinmunes, y para profilaxis de trasplante, en base a la ocupación de la BTK y las tasas de resíntesis de la y/o tasas de resíntesis de la BTK para células B en diversas enfermedades, compartimento de tejidos, incluyendo médula ósea y nódulos linfáticos.
ARP150102547A 2014-08-07 2015-08-07 Métodos para tratar cánceres, enfermedades inmunes y autoinmunes, y enfermedades inflamatorias en base a la tasa de ocupación de la tirosin quinasa de bruton (btk) y a la tasa de resíntesis de la tirosin quinasa de bruton (btk) AR101476A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201462034762P 2014-08-07 2014-08-07

Publications (1)

Publication Number Publication Date
AR101476A1 true AR101476A1 (es) 2016-12-21

Family

ID=54015142

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP150102547A AR101476A1 (es) 2014-08-07 2015-08-07 Métodos para tratar cánceres, enfermedades inmunes y autoinmunes, y enfermedades inflamatorias en base a la tasa de ocupación de la tirosin quinasa de bruton (btk) y a la tasa de resíntesis de la tirosin quinasa de bruton (btk)

Country Status (4)

Country Link
US (4) US20170143712A1 (es)
AR (1) AR101476A1 (es)
TW (2) TW201618783A (es)
WO (2) WO2016020901A1 (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2826950T3 (es) 2009-05-27 2021-05-19 Ptc Therapeutics Inc Métodos para tratar cáncer y afecciones no neoplásicas
JP7145761B2 (ja) * 2016-04-22 2022-10-03 クレイジュ・メディカル・カンパニー・リミテッド 細胞免疫療法の組成物および方法
JP2020511462A (ja) * 2016-12-03 2020-04-16 ジュノー セラピューティクス インコーポレイテッド キナーゼ阻害剤との組み合わせで治療用ｔ細胞を使用するための方法および組成物
WO2019014684A1 (en) * 2017-07-14 2019-01-17 Ohio State Innovation Foundation EXPANSION OF IMMUNE CELLS WITH INTERLEUKIN-INDUCIBLE T CELL KINASE-INHIBITING COMPOUNDS
KR20200035292A (ko) * 2017-08-01 2020-04-02 피티씨 테라퓨틱스, 인크. 혈액 암 치료에 사용하기 위한 dhodh 억제제
CZ2017787A3 (cs) 2017-12-08 2019-06-19 Zentiva, K.S. Farmaceutické kompozice obsahující ibrutinib
EP3789040A4 (en) * 2018-04-27 2022-03-09 ONO Pharmaceutical Co., Ltd. PREVENTIVE AND/OR THERAPEUTIC AGENT FOR AUTOIMMUNE DISEASES WITH A COMPOUND WITH BTK INHIBITING ACTIVITY AS AN INGREDIENT
US11633554B1 (en) * 2019-06-11 2023-04-25 Luca Puviani Adaptive systems and methods for delivery of a medicament
JP7649311B2 (ja) * 2020-01-02 2025-03-19 ディザル（ジァンスー）ファーマシューティカル・カンパニー・リミテッド Ｂｔｋ阻害薬
EP4284434A4 (en) * 2021-01-30 2024-12-25 BeiGene Switzerland GmbH METHODS FOR TREATING CHRONIC ACTIVE ANTIBODY-MEDIATED REJECTION USING BTK INHIBITORS
JP2022177821A (ja) * 2021-05-18 2022-12-01 ネクストシア インコーポレイテッド キナーゼ阻害剤療法と関連した、遺伝的耐性を克服し、治療効果を向上させ、安全性リスクを最小化する方法
EP4463163A4 (en) * 2022-01-14 2025-09-10 Telios Pharma Inc METHODS OF TREATING MYELOPROLIFERATIVE DISORDERS BASED ON BTK OCCUPATION AND RESYNTHESIS RATE
US20250360130A1 (en) 2024-05-21 2025-11-27 Telios Pharma Inc. Methods of treating indolent systemic mastocytosis
US12303604B1 (en) 2024-10-16 2025-05-20 Currax Pharmaceuticals Llc Pharmaceutical formulations comprising naltrexone and/or bupropion

Family Cites Families (169)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2805977A (en) 1955-01-04 1957-09-10 Smith Kline French Lab Sustained release pharmaceutical preparation
US2951792A (en) 1959-11-18 1960-09-06 Smith Kline French Lab Sustained release pharmaceutical tablets
US3065143A (en) 1960-04-19 1962-11-20 Richardson Merrell Inc Sustained release tablet
US3147187A (en) 1962-09-10 1964-09-01 Don Hall Lab Sustained release pharmaceutical
NL297631A (es) 1963-06-03
US3374146A (en) 1966-04-18 1968-03-19 American Cyanamid Co Sustained release encapsulation
US3773920A (en) 1971-07-14 1973-11-20 Nikken Chemicals Co Ltd Sustained release medicinal composition
US3901969A (en) 1973-09-10 1975-08-26 Union Corp Sustained release of methantheline
US3911100A (en) 1973-09-10 1975-10-07 Union Corp Sustained release of methantheline
US3901968A (en) 1973-09-10 1975-08-26 Union Corp Sustained release of methantheline
US4178361A (en) 1973-09-10 1979-12-11 Union Corporation Sustained release pharmaceutical composition
JPS55153715A (en) 1979-05-18 1980-11-29 Nikken Kagaku Kk Prolonged granule of theophylline
JPS5846019A (ja) 1981-09-14 1983-03-17 Kanebo Ltd 持続性ニフエジピン製剤
US4690682A (en) 1983-04-15 1987-09-01 Damon Biotech, Inc. Sustained release
US4777049A (en) 1983-12-01 1988-10-11 Alza Corporation Constant release system with pulsed release
US4674480A (en) 1984-05-25 1987-06-23 Lemelson Jerome H Drug compositions and methods of applying same
US4781919A (en) 1984-06-18 1988-11-01 Schering Corporation Sustained release dosage form
EP0190833B1 (en) 1985-02-07 1991-03-27 Takeda Chemical Industries, Ltd. Method for producing microcapsule
US4845123A (en) 1985-08-05 1989-07-04 The Ohio State University Reduction in vivo of the inappropriate levels of endogenous and environmental-derived compounds by sustained-release inhibitors of β-g
US4753801A (en) 1985-10-25 1988-06-28 Eli Lilly And Company Sustained release tablets
JPS62169723A (ja) 1986-01-22 1987-07-25 Teisan Seiyaku Kk 徐放化製剤
US4837032A (en) 1986-02-04 1989-06-06 Farval Ag Theophylline sustained release tablet
US5238686A (en) 1986-03-27 1993-08-24 Kinaform Technology, Inc. Sustained-release pharmaceutical preparation
JPH0794384B2 (ja) 1986-09-01 1995-10-11 帝国製薬株式会社 徐放性口腔内用製剤
JPH0819004B2 (ja) 1986-12-26 1996-02-28 日清製粉株式会社 徐放性医薬製剤
US4968508A (en) 1987-02-27 1990-11-06 Eli Lilly And Company Sustained release matrix
US5391381A (en) 1987-06-25 1995-02-21 Alza Corporation Dispenser capable of delivering plurality of drug units
ZA885069B (en) 1987-07-24 1989-03-29 Fujisawa Pharmaceutical Co Sustained-release percutaneous preparations
GB8812490D0 (en) 1988-05-26 1988-06-29 Agricultural & Food Res Delayed release formulations
US4988679A (en) 1989-01-03 1991-01-29 Leonard Chavkin Liquid sustained release composition
US5002774A (en) 1989-06-08 1991-03-26 Erbamont, Inc. Sustained release pharmaceutical tablet
US5538739A (en) 1989-07-07 1996-07-23 Sandoz Ltd. Sustained release formulations of water soluble peptides
EP0418565B1 (en) 1989-09-21 1994-11-30 American Cyanamid Company Pulsatile once-a-day delivery system for minocycline
US5136968A (en) 1990-01-02 1992-08-11 Pitney Bowes Inc. Sustained release ink dispenser
US5261896A (en) 1990-01-10 1993-11-16 Rochester Medical Corporation Sustained release bactericidal cannula
ATE183642T1 (de) 1991-10-04 1999-09-15 Yoshitomi Pharmaceutical Tablette mit verzögerter freisetzung
US5260068A (en) 1992-05-04 1993-11-09 Anda Sr Pharmaceuticals Inc. Multiparticulate pulsatile drug delivery system
US5795882A (en) 1992-06-22 1998-08-18 Bone Care International, Inc. Method of treating prostatic diseases using delayed and/or sustained release vitamin D formulations
WO1994006452A1 (en) 1992-09-21 1994-03-31 The Upjohn Company Sustained-release protein formulations
EP0669127B1 (en) 1992-11-18 1999-08-11 Fujisawa Pharmaceutical Co., Ltd. Prolonged-action pharmaceutical preparation
US5260069A (en) 1992-11-27 1993-11-09 Anda Sr Pharmaceuticals Inc. Pulsatile particles drug delivery system
TW333456B (en) 1992-12-07 1998-06-11 Takeda Pharm Ind Co Ltd A pharmaceutical composition of sustained-release preparation the invention relates to a pharmaceutical composition of sustained-release preparation which comprises a physiologically active peptide.
US6087324A (en) 1993-06-24 2000-07-11 Takeda Chemical Industries, Ltd. Sustained-release preparation
US6447796B1 (en) 1994-05-16 2002-09-10 The United States Of America As Represented By The Secretary Of The Army Sustained release hydrophobic bioactive PLGA microspheres
US5767153A (en) 1995-06-07 1998-06-16 Insite Vision Incorporated Sustained release emulsions
DE69627365T2 (de) 1995-09-29 2004-02-12 Lam Pharmaceutical Corp. Verabreichungssystem mit verzoegerter freisetzung sowie langwirkende narkotische analgetika und antagonisten
US6007843A (en) 1995-09-29 1999-12-28 Lam Pharmaceuticals Corp. Sustained release delivery system
US5773031A (en) 1996-02-27 1998-06-30 L. Perrigo Company Acetaminophen sustained-release formulation
IE960308A1 (en) 1996-04-23 1997-11-05 Kinerton Ltd Sustained release ionic conjugate
US6419961B1 (en) 1996-08-29 2002-07-16 Takeda Chemical Industries, Ltd. Sustained release microcapsules of a bioactive substance and a biodegradable polymer
US5914134A (en) 1997-01-27 1999-06-22 Wockhardt Europe Limited Process for the pulsatile delivery of diltiazem HCL and product produced thereby
AU5678398A (en) 1997-01-29 1998-08-18 Takeda Chemical Industries Ltd. Sustained-release microspheres, their production and use
JP3611456B2 (ja) 1997-09-30 2005-01-19 日研化学株式会社 テオフィリン徐放性錠剤
US6056977A (en) 1997-10-15 2000-05-02 Edward Mendell Co., Inc. Once-a-day controlled release sulfonylurea formulation
WO1999036099A1 (fr) 1998-01-16 1999-07-22 Takeda Chemical Industries, Ltd. Compositions a liberation controlee, leur procede de fabrication et leur utilisation
DE69912012T2 (de) 1998-01-30 2004-08-19 Shin-Etsu Chemical Co., Ltd. Pheromonspender mit verzögerter Abgabe
WO1999043300A1 (en) 1998-02-25 1999-09-02 Abbott Laboratories Butorphanol sustained release formulations
US6677319B1 (en) 1998-08-06 2004-01-13 Wolfgang Stremmel Phosphatidylcholine as medication with protective effect large intestinal mucosa
US6303607B1 (en) 1998-09-10 2001-10-16 Cv Therapeutics, Inc. Method for administering a sustained release ranolanolazine formulation
US20070148228A1 (en) 1999-02-22 2007-06-28 Merrion Research I Limited Solid oral dosage form containing an enhancer
US6410052B1 (en) 1999-03-30 2002-06-25 Purdue Research Foundation Tea catechins in sustained release formulations as cancer specific proliferation inhibitors
CA2378829A1 (en) 1999-07-20 2001-01-25 Merck & Co., Inc. Sustained release drug dispersion delivery device
HUP0203060A3 (en) 1999-08-18 2003-11-28 Sod Conseils Rech Applic Sustained release complex of a peptide, process for its preparation and pharmaceutical composition containing the same
US6458387B1 (en) 1999-10-18 2002-10-01 Epic Therapeutics, Inc. Sustained release microspheres
US20020004070A1 (en) 2000-02-24 2002-01-10 Rudnic Edward M. Antineoplastic product, use and formulation thereof
GB0007419D0 (en) 2000-03-27 2000-05-17 Smithkline Beecham Gmbh Composition
US6375972B1 (en) 2000-04-26 2002-04-23 Control Delivery Systems, Inc. Sustained release drug delivery devices, methods of use, and methods of manufacturing thereof
US7838032B2 (en) 2000-04-28 2010-11-23 Reckitt Benckiser Inc. Sustained release of guaifenesin
KR100392501B1 (ko) 2000-06-28 2003-07-22 동국제약 주식회사 다중 에멀젼법에 의한 서방출성 미립구의 제조방법
DK1345595T3 (da) 2000-09-29 2007-09-10 Solvay Pharm Bv Ionstyrke-uafhængig farmaceutisk formulering med depotfrigivelse
US7108859B2 (en) 2000-10-13 2006-09-19 Advancis Pharmaceutical Corporation Antineoplastic product, use and formulation thereof
US7105174B2 (en) 2000-10-13 2006-09-12 Advancis Pharmaceutical Corporation Multiple-delayed release anti-neoplastic product, use and formulation thereof
US8470359B2 (en) 2000-11-13 2013-06-25 Qlt Usa, Inc. Sustained release polymer
US6756049B2 (en) 2000-12-29 2004-06-29 Bausch & Lomb Incorporated Sustained release drug delivery devices
JP2004521882A (ja) 2001-01-03 2004-07-22 ボシュ・アンド・ロム・インコーポレイテッド 組立式透過性プラグを備えた徐放薬剤送達装置
JP4184082B2 (ja) 2001-01-03 2008-11-19 ボシュ・アンド・ロム・インコーポレイテッド 複数の薬剤を備えた徐放薬剤送達装置
WO2002058667A2 (en) 2001-01-26 2002-08-01 Bausch & Lomb Incorporated Improved process for the production of sustained release drug delivery devices
US20020172712A1 (en) 2001-03-19 2002-11-21 Alan Drizen Antiemetic, anti-motion sustained release drug delivery system
US7318931B2 (en) 2001-06-21 2008-01-15 Genentech, Inc. Sustained release formulation
AUPR602401A0 (en) 2001-06-29 2001-07-26 Smart Drug Systems Inc Sustained release delivery system
TWI225416B (en) 2001-06-29 2004-12-21 Takeda Chemical Industries Ltd Sustained-release composition and process for producing the same
AUPR602501A0 (en) 2001-06-29 2001-07-26 Smart Drug Systems Inc Sustained release pharmaceutical composition
FR2827517B1 (fr) 2001-07-23 2003-10-24 Bioalliance Pharma Systemes therapeutiques bioadhesifs a liberation prolongee
US20050129728A1 (en) 2001-09-11 2005-06-16 Martinod Serge R. Sustained release pharmaceutical composition
NZ530550A (en) 2001-09-11 2004-11-26 Smart Drug Systems Inc Preparation of sustained release pharmaceutical composition
AUPR951501A0 (en) 2001-12-14 2002-01-24 Smart Drug Systems Inc Modified sustained release pharmaceutical system
AU2003201410B2 (en) 2002-01-24 2008-07-03 Virbac Corporation Sustained release pharmaceutical composition
NZ538928A (en) 2002-09-27 2006-10-27 Zentaris Gmbh Administration form for pharmaceutically active peptides with sustained release of active ingredient, and method for the production thereof
US20080193590A1 (en) 2002-11-06 2008-08-14 Fiberstar Inc., Incorporated Highly refined cellulose neutraceutical compostions and methods of use
ITRM20030074A1 (it) 2003-02-21 2004-08-22 Pharmacia Italia Spa Formulazioni semisolide a rilascio immediato intese
JP4898431B2 (ja) 2003-04-29 2012-03-14 ザ ジェネラル ホスピタル コーポレイション 複数薬物の持続放出のための方法およびデバイス
US7405295B2 (en) 2003-06-04 2008-07-29 Cgi Pharmaceuticals, Inc. Certain imidazo[1,2-a]pyrazin-8-ylamines and method of inhibition of Bruton's tyrosine kinase by such compounds
WO2005005429A1 (en) 2003-06-30 2005-01-20 Cellular Genomics, Inc. Certain heterocyclic substituted imidazo[1,2-a]pyrazin-8-ylamines and methods of inhibition of bruton’s tyrosine kinase by such compounds
ATE525377T1 (de) 2003-10-15 2011-10-15 Osi Pharm Inc Imidazoä1,5-aüpyrazine als inhibitoren von tyrosinkinase
US8197846B2 (en) 2003-11-10 2012-06-12 Astellas Pharma Inc. Sustained release pharmaceutical composition
TW200529890A (en) 2004-02-10 2005-09-16 Takeda Pharmaceutical Sustained-release preparations
EP1750683B1 (en) 2004-04-23 2013-01-09 Amgen Inc. Sustained release formulations
WO2005117934A1 (en) 2004-05-31 2005-12-15 Smart Drug Systems Inc Sustained release composition
WO2005123120A1 (en) 2004-06-16 2005-12-29 Smart Drug Systems Inc. Sustained release vaccine composition
TW200613012A (en) 2004-07-02 2006-05-01 Takeda Pharmaceuticals Co Sustained-release composition, process for producing the same and use of the same
CN101039661A (zh) 2004-09-09 2007-09-19 普西考法玛公司 用于肼苯哒嗪缓释的药物组合物及其作为癌症治疗载体的用途
US8318210B2 (en) 2005-02-28 2012-11-27 Neos Therapeutics, Lp Compositions and methods of making sustained release liquid formulations
EP1906929A2 (en) 2005-04-25 2008-04-09 Amgen Inc. Biodegradable peptide sustained release compositions containing porogens
US20070059359A1 (en) 2005-06-07 2007-03-15 Thomas Backensfeld Immediate-release and high-drug-load pharmaceutical formulations of non-micronised (4-chlorophenyl)[4-(4-pyridylmethyl)phthalazin-1-yl] and salts thereof
EP1731154A1 (en) 2005-06-07 2006-12-13 Schering Aktiengesellschaft Immediate-release and high-drug-load pharmaceutical formulations of micronised (4-chlorophenyl)|4-(4-pyridylmethyl)pht halazin-1-yl| and salts thereof
EP1731153A1 (en) 2005-06-07 2006-12-13 Schering Aktiengesellschaft Immediate-release and high-drug-load pharmaceutical formulations of non-micronised (4-chlorophenyl)¬4-(4-pyridylmethyl)phthalazin-1-yl| and salts thereof
US20060275365A1 (en) 2005-06-07 2006-12-07 Thomas Backensfeld Immediate-release and high-drug-load pharmaceutical formulations of micronised (4-chlorophenyl) [4-(4-pyridylmethyl)phthalazin-1-yl] and salts thereof
US20060280795A1 (en) 2005-06-08 2006-12-14 Dexcel Pharma Technologies, Ltd. Specific time-delayed burst profile delivery system
WO2007036952A2 (en) 2005-07-01 2007-04-05 Rubicon Research Pvt Ltd. Novel sustained release dosage form
US8277840B2 (en) 2005-07-22 2012-10-02 Emcure Pharmaceuticals Limited Sustained release formulation of alprazolam
US20070092559A1 (en) 2005-10-24 2007-04-26 Jinghua Yuan Liquid dosage forms having enteric properties of delayed and then sustained release
US20090061006A1 (en) 2006-03-31 2009-03-05 Carola Leuschner Layered Nanoparticles for Sustained Release of Small Molecules
US7704977B2 (en) 2006-04-07 2010-04-27 Merrion Research Iii Limited Solid oral dosage form containing an enhancer
US20070292512A1 (en) 2006-06-09 2007-12-20 Merrion Research Ii Limited Solid Oral Dosage Form Containing an Enhancer
MX2008015917A (es) 2006-06-22 2009-01-13 Novartis Ag Formulaciones de liberacion sostenida de inhibidores de aromatasa.
US20110020457A1 (en) 2006-08-14 2011-01-27 Wayne State University Polymer-surfactant nanoparticles for sustained release of compounds
DK2529622T3 (en) 2006-09-22 2018-05-07 Pharmacyclics Llc INHIBITORS OF BRUTON-TYROSINKINASE
US20080268045A1 (en) 2006-11-09 2008-10-30 Proprius Pharmaceuticals, Inc. Sustained release methotrexate formulations and methods of use thereof
US8921326B2 (en) 2006-12-18 2014-12-30 Takeda Pharmaceutical Company Limited Sustained-release composition and method for producing the same
CA2674610C (en) 2007-01-11 2013-06-18 Xenoport, Inc. Sustained release oral dosage forms of a prodrug of r-baclofen and methods of treatment
JP5429642B2 (ja) 2007-06-12 2014-02-26 アレン，クリスティン 薬剤の局所導出を対象とした注射可能なポリマー／脂質ブレンド
EP2222363B1 (en) 2007-10-30 2017-03-15 UTI Limited Partnership Method and system for sustained-release of sclerosing agent
US7894450B2 (en) 2007-12-31 2011-02-22 Nortel Network, Ltd. Implementation of VPNs over a link state protocol controlled ethernet network
US8193182B2 (en) 2008-01-04 2012-06-05 Intellikine, Inc. Substituted isoquinolin-1(2H)-ones, and methods of use thereof
WO2009088990A1 (en) 2008-01-04 2009-07-16 Intellikine, Inc. Certain chemical entities, compositions and methods
US8012508B2 (en) 2008-01-15 2011-09-06 Abbott Cardiovascular Systems Inc. Method of targeting sustained release formulations of therapeutic agents to treat lung diseases
US8580298B2 (en) 2008-06-09 2013-11-12 Vivus, Inc. Low dose topiramate/phentermine composition and methods of use thereof
NZ589843A (en) 2008-06-27 2012-12-21 Avila Therapeutics Inc Pyrimidine heteroaryl compounds and uses thereof as protein kinase inhibitors
EP2299953B1 (en) 2008-07-14 2017-04-12 Polypid Ltd. Sustained-release drug carrier composition
MX2011003740A (es) 2008-10-07 2011-05-02 Astrazeneca Uk Ltd Formulacion farmaceutica - 514.
ES2776126T3 (es) 2008-12-15 2020-07-29 Pfizer Nanopartículas de circulación prolongada para la liberación sostenida de agentes terapéuticos
KR20110117216A (ko) 2009-03-03 2011-10-26 제노포트 인코포레이티드 Ｒ-바클로펜 전구약물의 서방형 경구 투약 형태
AU2010272167B2 (en) 2009-07-14 2016-11-17 Polypid Ltd. Sustained-release drug carrier composition
US8831023B2 (en) 2009-07-29 2014-09-09 Cisco Technology, Inc. Low latency mesh network
US10485792B2 (en) 2009-08-26 2019-11-26 Hadasit Medical Research Services & Development Limited Sustained release delivery systems for the prevention and treatment of head and neck cancers
MA33910B1 (fr) 2009-12-22 2013-01-02 Takeda Pharmaceutcal Company Ltd Formulation à libération prolongée
US20110183944A1 (en) 2010-01-28 2011-07-28 Paul Ashton SUSTAINED-RELEASE NSAID/HMG CoA REDUCTASE INHIBITOR COMPOSITIONS
GB201003731D0 (en) 2010-03-05 2010-04-21 Univ Strathclyde Immediate/delayed drug delivery
RU2598852C2 (ru) 2010-06-23 2016-09-27 Ханми Сайенс Ко., Лтд. Новые конденсированные пиримидиновые производные для ингибирования тирозинкиназной активности
KR20130097088A (ko) 2010-06-25 2013-09-02 다케다 야쿠힌 고교 가부시키가이샤 서방성 제제
EP4202040A1 (en) 2010-07-01 2023-06-28 Regenerative Research Foundation Methods for culturing undifferentiated cells using sustained release compositions
ES2617763T3 (es) 2010-08-10 2017-06-19 Celgene Avilomics Research, Inc. Sal de besilato de un inhibidor de BTK
US20130230587A1 (en) 2010-11-10 2013-09-05 Rubicon Research Private Limited Sustained release compositions
US20140328895A1 (en) 2011-03-29 2014-11-06 Yissum Research Development Company Of The Hebrew University Of Jerusalem, Ltd. Film-forming composition for a ph-dependant sustained release of the active agent
CA2760174A1 (en) 2011-12-01 2013-06-01 Pharmascience Inc. Protein kinase inhibitors and uses thereof
SG193406A1 (en) 2011-04-04 2013-10-30 Pharmascience Inc Protein kinase inhibitors
BR112013029508B1 (pt) 2011-05-17 2022-05-03 Principia Biopharma, Inc. Composto, composição farmacêutica, e, uso do referido composto
AU2012325370A1 (en) 2011-06-10 2014-01-30 Ramscor, Inc. Conveniently injectable or implantable sustained-release antioxidant formulations for therapies of ocular maladies or cancer
SI2734522T1 (sl) 2011-07-19 2019-03-29 Merck Sharp & Dohme B.V. 4-IMIDAZOPIRIDAZIN-1-IL-BENZAMIDI IN 4-IMIDAZOTRIAZIN-1-IL-BENZAMIDI kot BTK-INHIBITORJI
WO2013010869A1 (en) 2011-07-19 2013-01-24 Msd Oss B.V. 4-imidazopyridazin-1-yl-benzamides and 4-imidazotriazin-1-yl-benzamides btk-inhibitors
CN103874480A (zh) 2011-08-12 2014-06-18 阿森迪斯药物股份有限公司 前列环素的缓释组合物
DK2773354T3 (da) 2011-11-01 2019-08-05 Resverlogix Corp Oralformuleringer med øjeblikkelig frigivelse for substituerede quinazolinoner
DK2786996T3 (en) 2011-11-29 2016-12-19 Ono Pharmaceutical Co Hydrochloride PURINONDERIVAT
US20150087671A1 (en) 2012-05-16 2015-03-26 Micell Technologies, Inc. Low burst sustained release lipophilic and biologic agent compositions
AU2013264767A1 (en) 2012-05-22 2014-11-27 Laila Pharmaceuticals Pvt. Ltd. Novel highly bioavailable, water soluble and sustained release nanoformulations of hydrophobic plant derived compounds and extracts
US9138411B2 (en) 2012-08-31 2015-09-22 University Of North Texas Health Science Center At Fort Worth Curcumin-ER, a liposomal-PLGA sustained release nanocurcumin for minimizing QT prolongation for cancer therapy
US20140100283A1 (en) 2012-10-05 2014-04-10 Atlantic Pro Nutrients, Inc. dba XYMOGEN Method to Increase Absorption and Bioavailability of Oral Glutathione
BR112015008042A2 (pt) 2012-10-11 2017-07-04 Pharmacyclics Inc diagnósticos complementares para terapia com inibidor de quinase da família tec
NZ708157A (en) 2012-11-15 2019-07-26 Incyte Holdings Corp Sustained-release dosage forms of ruxolitinib
WO2014113377A1 (en) 2013-01-15 2014-07-24 Ironwood Pharmaceuticals, Inc. Gastro-retentive sustained-release oral dosage form of a bile acid sequestrant
AU2014218903A1 (en) 2013-02-20 2015-09-17 Prelief Inc. Methods and compositions of treating and preventing intestinal injury and diseases related to tight junction dysfunction
JP6041823B2 (ja) 2013-03-16 2016-12-14 ファイザー・インク トファシチニブの経口持続放出剤形
CN104884458B (zh) 2013-04-25 2017-04-12 百济神州有限公司 作为蛋白质激酶抑制剂的稠合杂环化合物
US20150005277A1 (en) 2013-06-28 2015-01-01 Beigene, Ltd. Protein Kinase Inhibitors and Uses Thereof
MX394928B (es) 2013-08-07 2025-03-24 Incyte Holdings Corp Formas de dosificacion de liberacion prolongada para un inhibidor de jak 1 (cinasa de janus 1).
WO2015025312A1 (en) 2013-08-21 2015-02-26 Cannabics Pharmaceuticals Inc Compositions for combined immediate and sustained release of cannabinoids, methods of manufacture and use thereof
UA119335C2 (uk) 2013-12-11 2019-06-10 Айронвуд Фармасьютикалз, Інк. Композиції лінаклотиду з затриманим вивільненням
WO2015110923A2 (en) * 2014-01-21 2015-07-30 Acerta Pharma B.V. Methods of treating chronic lymphocytic leukemia and small lymphocytic leukemia usng a btk inhibitor
US10272083B2 (en) * 2014-01-21 2019-04-30 Acerta Pharma B.V. Methods of treating chronic lymphocytic leukemia and small lymphocytic leukemia using a BTK inhibitor

Also Published As

Publication number Publication date
US20170143712A1 (en) 2017-05-25
US20210322408A1 (en) 2021-10-21
TW201705959A (zh) 2017-02-16
WO2016020901A1 (en) 2016-02-11
WO2017025814A1 (en) 2017-02-16
US20250090525A1 (en) 2025-03-20
US20190314369A1 (en) 2019-10-17
TW201618783A (zh) 2016-06-01

Similar Documents

Publication Publication Date Title
AR101476A1 (es) Métodos para tratar cánceres, enfermedades inmunes y autoinmunes, y enfermedades inflamatorias en base a la tasa de ocupación de la tirosin quinasa de bruton (btk) y a la tasa de resíntesis de la tirosin quinasa de bruton (btk)
CY1124311T1 (el) Παρεμποδιστες dna-pk
CL2016001055A1 (es) Compuestos derivados de fenil-aminopirimidina, inhibidores de la tirosina quinasa de bruton (btk), composicion farmaceutica; combinacion farmaceutica; útiles en el tratamiento de enfermedades autoinmunes, inflamatorias, alergicas, de las vias aereas, entre otras.
CY1119840T1 (el) Δικυκλικως υποκατεστημενες ουρακιλες και η χρηση αυτων
CL2018001152A1 (es) Composiciones y métodos para el tratamiento del cáncer
MX386752B (es) Agonistas del receptor farnesoide x y usos de los mismos.
EA201792529A1 (ru) Ингибиторы тирозинкиназы
PH12017500583B1 (en) Dihydropyrrolopyridine inhibitors of ror-gamma
MX2020004506A (es) Derivados del bipirazol como inhibidores de janus cinasa (jak).
MX381283B (es) Tratamiento de pénfigo.
PH12016501457B1 (en) Dihydropyrrolopyridine inhibitors of ror-gamma
MX2015009058A (es) Composiciones y metodos para tratar la inflamacion cronica y las enfermedades inflamatorias.
MX385332B (es) Moduladores de ror-gamma.
TW201613919A (en) Inhibitors of Bruton's tyrosine kinase
MX372673B (es) Un inhibidor de btk para usarse en el tratamiento de penfigo y sales y formas sólidas del mismo.
MX2017015574A (es) Inhibidores de tirosina quinasa de bruton.
SMT202000305T1 (it) Composizioni per l'uso in metodi per il trattamento di ferite, disturbi e malattie della pelle
MX375752B (es) Inhibidores de tirosina quinasa de bruton.
MX377340B (es) Composiciones en solución sólida y uso en el tratamiento de enfermedades cardiovasculares.
MX373129B (es) Derivados de indolizina como inhibidores de fosfoinositido-3 cinasas.
UY35625A (es) Compuestos de tetrahidrocarbazol y carbazol carboxamida sustituidos como inhibidores de quinasa
MX2015009045A (es) Composiciones y metodos para tratar el dolor severo.
MX2019003134A (es) Terapia de combinacion.
MX2018005825A (es) Celulas inmunes modificadas y usos de las mismas.
CY1124492T1 (el) 7-υποκατεστημενα 1-αρυλο-ναφθυριδιν-3-καρβοξαμιδια και η χρηση αυτων

Legal Events

Date Code Title Description
FB Suspension of granting procedure